A comparative computer simulation study of three different sparse-sampling methods for the estimation of steady-state area under the concentration-time curve (AUC) and maximum concentration (C-max) in toxicokinetics

被引:15
作者
Mahmood, I
机构
[1] Off. Clin. Pharmacol. Biopharmaceut., Div. of Pharmaceutical Evaluation I, Woodmont Office Center II, Rockville, MD 20852
关键词
D O I
10.1021/js960450i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A limited-sampling method is proposed to estimate the area under the curve (AUC) of concentration Versus time and maximum concentration (C-max,) following single or multiple oral doses of a hypothetical drug. The plasma concentration versus time data sets for 50 animals were generated by simulation. The limited-sampling model (LSM) was developed with samples from 10 animals at a single time point. The model was validated in another 40 animals who received either a 500-mg single dose or multiple doses orally. The model provided good population mean estimates of AUC and C-max. The proposed method was compared with the existing two methods; they are, naive sampling (five time points) and optimal sampling (three time points). The method described here may be useful in estimating AUC and C-max with one or two samples in toxicokinetic studies following single or multiple oral dosing without detailed pharmacokinetic studies.
引用
收藏
页码:579 / 583
页数:5
相关论文
共 17 条
[1]   24-HOUR SERUM LITHIUM LEVEL AS A PROGNOSTICATOR OF DOSAGE REQUIREMENTS [J].
COOPER, TB ;
BERGNER, PEE ;
SIMPSON, GM .
AMERICAN JOURNAL OF PSYCHIATRY, 1973, 130 (05) :601-603
[2]  
DARGENIO D, 1992, ADAPT 2 USERS GUIDE
[3]   AN EVALUATION OF OPTIMAL SAMPLING STRATEGY AND ADAPTIVE STUDY DESIGN [J].
DRUSANO, GL ;
FORREST, A ;
SNYDER, MJ ;
REED, MD ;
BLUMER, JL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :232-238
[4]   A LIMITED SAMPLING MODEL FOR THE PHARMACOKINETICS OF ETOPOSIDE GIVEN ORALLY [J].
GENTILI, D ;
ZUCCHETTI, M ;
TORRI, V ;
SESSA, C ;
DEJONG, J ;
CAVALLI, F ;
DINCALCI, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (06) :482-486
[5]  
Landaw E., 1985, VARIABILITY DRUG THE, P187
[6]  
Mahmood I, 1997, BIOPHARM DRUG DISPOS, V18, P117
[7]  
MAHMOOD I, UNPUB BR J CLIN PHAR
[8]  
PAI S, 1996, PHARMACEUT RES, V13, P1253
[9]  
RATAIN MJ, 1988, CANCER RES, V48, P4127
[10]  
RATAIN MJ, 1987, CANCER TREAT REP, V71, P935